Executive Management Team

Born: 1961

Employed since: 2013

Other assignments: Board member of Egetis Therapeutics AB.

Education: Pharmacist; Ph.D. in biopharmacy and pharmacokinetics at Uppsala University, Sweden.

Experience and prior assignments: More than 35 years of experience in drug development. Executive positions at Astra/AstraZeneca, including Vice President responsible for the product portfolio in neurodegenerative diseases. Board member of SP Process Development AB.

Member of BioArctic’s senior management since: 2013

Total holdings* and warrants in BioArctic: 84,800 Class B shares. Warrants granting acquisition rights to 90,000 Class B shares (2019/2028 program). 10,000 performance-based share units (2023/2026 program).

Born: 1971

Employed at the company since: 2023

Other assignments: Board member of Cantargia Ab and Affibody Medical AB.

Experience and prior assignments: Extensive experience as CFO for life science companies listed on the Stockholm stock exchange and has previously served as CFO for Oncopeptides, Wilson Therapeutics and RaySearch Laboratories and has also held the position of Head of Investor Relations and different positions within business development at Swedish Orphan Biovitrum. 

Education: Master of Science in Engineering Physics from the Royal Institute of Technology (KTH) in Stockholm and Bachelor of Science in Business administration and economics from Stockholm University

Member of BioArctic’s senior management since: 2023

Total holdings* and warrants in BioArctic: 1000 Class B shares and warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program). 3,000 performance-based share units (2023/2026 program).

Born: 1961

Employed since: 2019 (contracted since 2014)

Other assignments: Manages her own consulting company focusing on HR.

Education: B.Sc. Human Resource Development and Labor Relations with a specialization in labor rights from Lund University, Sweden.

Experience and prior assignments: Over 30 years of experience as HR consultant and HR manager in educational organizations and pharma companies such as Pharmacia and Novartis.

Member of BioArctic’s senior management since: 2019

Total holdings* and warrants in BioArctic: 0 shares. Warrants granting acquisition rights to 15,000 Class B shares (2019/2028 program). 3,000 performance-based share units (2023/2026 program).

Born: 1976

Employed since: 2020

Other assignments: –

Education: M.Sc. Molecular Biotechnology and B.A. in Business Administration from Uppsala University

Experience and prior assignments:20 years of experience globally in communications. Has held senior positions in companies such as Sobi, Ovako and Elekta.

Member of BioArctic’s senior management since: 2020

Total holdings* and warrants in BioArctic: 11 055 Class B shares. Warrants granting acquisition rights to 8000 Class B shares (2019/2028 program). 3,000 performance-based share units (2023/2026 program).

Born: 1972

Employed since: 2012

Other assignments: –

Education: Ph.D. in Physiology, Stockholm University; Licentiate degree in physiology, Stockholm University; Master’s degree in biology, Stock-holm University, Sweden.

Experience and prior assignments:Over 20 years of experience in drug development in executive positions in R&D, and development in the global pharma and biotech industry.

Member of BioArctic’s senior management since: 2012

Total holdings* and warrants in BioArctic: 27 355 Class B shares. Warrants granting acquisition rights to 8000 Class B shares (2019/2028 program). 3,000 performance-based share units (2023/2026 program).

Born: 1959

Employed since: 2020 (contracted since 2018)

Other assignments: –

Education: Law degree at Uppsala university

Experience and prior assignments: Close to 30 years of experience from senior and leading roles as in-house counsel in the research-oriented global pharmaceutical industry, e.g. Astra/AstraZeneca, as well as own managed consulting operation.

Member of BioArctic’s Group Management team since: 2023

Total holdings* och warrants i BioArctic: 0 shares. Warrants granting acquisition rights to 8,000 Class B-shares (program 2019/2028). 3,000 performance-based share units (2023/2026 program).

*Includes holdings by self, closely associated persons, controlled companies or in capital insurance accounts.

Born: 1968

Employed since: 2021 (contracted since 2020)

Other assignments: Board member of Index Pharmaceuticals AB.

Education: B.A. in Business Administration from Uppsala University, Sweden.

Experience and prior assignments: More than 25 years of experience in leading commercial roles in the global pharmaceutical industry. Previously CEO for Sanofi AB and General Manager, Nordics & Baltics General Medicines.

Member of BioArctic’s senior management since: 2021

Total holdings* and warrants in BioArctic: 9,300 Class B shares, privately and through Saimi AB. Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program). 3,000 performance-based share units (2023/2026 program).

Born: 1967

Employed since: 2012

Other assignments –

Education: Master of Chemical Engineering, KTH Royal Institute of Technology; Ph.D. in organic chemistry, KTH; Stockholm, Sweden.

Experience and prior assignments: Over 20 years of experience in drug development and 20 years of experience as R&D director in process development and GMP manufacturing. Former section manager in Process R&D at AstraZeneca.

Member of BioArctic’s senior management since: 2012

Total holdings* and warrants in BioArctic: 12, 470 shares Warrants granting acquisition rights to 14,000 Class B shares (2019/2028 program). 3,000 performance-based share units (2023/2026 program).

Born: 1959

Employed since: 2019 (contracted since 2016)

Other assignment: Senior Clinical Consultant at GKeller Consulting

Education: MD Uppsala University, PhD Karolinska Institute, Neurologist certified by the Swedish Medical Society, Diploma in Pharmaceutical Medicine EUCOR/ECPM.

Experience and prior assignments: Over 25 years of experience in the pharma industry, in leading positions in clinical research at AstraZeneca and H. Lundbeck. Chief Specialist ICR Neurology H Lundbeck A/S (2015–2017).

Member of BioArctic’s senior management since: 2020

Total holdings* and warrants in BioArctic: 5,700 Class B-shares. Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program). 3,000 performance-based share units (2023/2026 program).